Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: Optimization from lead compound to CH5137291

Prostate

Volumn 71, Issue 12, 2011, Pages 1344-1356

  Kawata, Hiromitsu ^a   Arai, Shinichi ^a   Nakagawa, Toshito ^a   Ishikura, Nobuyuki ^a   Nishimoto, Ayako ^a   Yoshino, Hitoshi ^a   Shiraishi, Takuya ^a   Tachibana, Kazutaka ^a   Nakamura, Ryo ^b   Sato, Haruhiko ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b Chugai Research Institute for Medical Science Inc   (Japan)

Author keywords

androgen receptor; antagonist; castration resistant; prostate cancer

Indexed keywords

ANDROGEN RECEPTOR ANTAGONIST; BICALUTAMIDE; CH 4933468; CH 5137291; CH 5138514; CH 5166623; DRUG METABOLITE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CONTROLLED STUDY; DRUG METABOLISM; DRUG MONITORING; FEMALE; HUMAN; HUMAN CELL; LIVER MICROSOME; MALE; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSACTIVATION; TUMOR XENOGRAFT;

ANDROGEN ANTAGONISTS; ANDROGEN RECEPTOR ANTAGONISTS; ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS; CARBAMATES; CELL NUCLEUS; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEAD; MALE; MICE; MICE, NUDE; MICE, SCID; NEOPLASM TRANSPLANTATION; NITRILES; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SULFONAMIDES; THIOHYDANTOINS; TOSYL COMPOUNDS; TRANSCRIPTION, GENETIC; TRANSLOCATION, GENETIC; TRANSPLANTATION, HETEROLOGOUS;

EID: 79960735140     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21351     Document Type: Article

References (41)

1. Bosetti C, Bertuccio P, Levi F, Lucchini F, Negri E, La Vecchia C,. Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis. Ann Oncol 2008; 19 (4): 631-640. (Pubitemid 351461031)
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59 (4): 225-249.
3. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T,. Cancer incidence and incidence rates in Japan in 2002: based on data from 11 population-based cancer registries. Jpn J Clin Oncol 2008; 38 (9): 641-648.
4. Qiu D, Katanoda K, Marugame T, Sobue T,. A Joinpoint regression analysis of long-term trends in cancer mortality in Japan (1958-2004). Int J Cancer 2009; 124 (2): 443-448.
5. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ,. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum Pathol 2000; 31 (5): 578-583. (Pubitemid 30323983)
6. Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, Vessella RL,. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003; 34 (7): 646-653. (Pubitemid 36875509)
7. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ,. Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program. Cancer Res 2004; 64 (24): 9209-9216. (Pubitemid 39665537)
8. Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S, Hirao Y,. Combined androgen blockade with bicalutamide for advanced prostate cancer: Long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 2009; 115 (15): 3437-3445.
9. Arai Y, Akaza H, Deguchi T, Fujisawa M, Hayashi M, Hirao Y, Kanetake H, Naito S, Namiki M, Tachibana M, Usami M, Ohashi Y,. Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: A multicenter, randomized, double-blind, comparative study. J Cancer Res Clin Oncol 2008; 134 (12): 1385-1396.
10. Fujii Y, Kawakami S, Masuda H, Kobayashi T, Hyochi N, Kageyama Y, Kihara K,. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy. BJU Int 2006; 97 (6): 1184-1189. (Pubitemid 43907318)
11. Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, DeWolf W, Balk S, Taplin ME, Bubley GJ,. High dose bicalutamide for androgen independent prostate cancer: Effect of prior hormonal therapy. J Urol 1998; 159 (1): 149-153. (Pubitemid 27525592)
12. Kucuk O, Fisher E, Moinpour CM, Coleman D, Hussain MH, Sartor AO, Chatta GS, Lowe BA, Eisenberger MA, Crawford ED,. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: A Southwest Oncology Group study (SWOG 9235). Urology 2001; 58 (1): 53-58. (Pubitemid 32633935)
13. Miyake H, Hara I, Eto H,. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU Int 2005; 96 (6): 791-795. (Pubitemid 41391382)
14. Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Kishikawa H, Ichikawa Y,. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer. Int J Urol 2007; 14 (3): 264-267. (Pubitemid 46423250)
15. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM,. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001; 61 (11): 4315-4319. (Pubitemid 32685750)
16. Attar RM, Takimoto CH, Gottardis MM,. Castration-resistant prostate cancer: Locking up the molecular escape routes. Clin Cancer Res 2009; 15 (10): 3251-3255.
17. Pienta KJ, Bradley D,. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006; 12 (6): 1665-1671.
18. Schroder FH,. Progress in understanding androgen-independent prostate cancer (AIPC): A review of potential endocrine-mediated mechanisms. Eur Urol 2008; 53 (6): 1129-1137.
19. Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS,. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res 2006; 66 (21): 10613-10620. (Pubitemid 44799785)
20. Haag P, Bektic J, Bartsch G, Klocker H, Eder IE,. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 2005; 96 (3-4): 251-258. (Pubitemid 41080506)
21. Liao X, Tang S, Thrasher JB, Griebling TL, Li B,. Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther 2005; 4 (4): 505-515. (Pubitemid 40601831)
22. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL,. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10 (1): 33-39. (Pubitemid 38524696)
23. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H,. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 1999; 81 (2): 242-251. (Pubitemid 29423702)
24. Kawata H, Ishikura N, Watanabe M, Nishimoto A, Tsunenari T, Aoki Y,. Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity. Prostate 2010; 70 (7): 745-754.
25. Yoshino H, Sato H, Tachibana K, Shiraishi T, Nakamura M, Ohta M, Ishikura N, Nagamuta M, Onuma E, Nakagawa T, Arai S, Ahn KH, Jung KY, Kawata H,. Structure-activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists. Bioorg Med Chem 2010; 18 (9): 3159-3168.
26. Korenchuk S, Lehr JE, L MC, Lee YG, Whitney S, Vessella R, Lin DL, Pienta KJ,. VCaP, a cell-based model system of human prostate cancer. In Vivo 2001; 15 (2): 163-168. (Pubitemid 32328191)
27. Loberg RD, St John LN, Day LL, Neeley CK, Pienta KJ,. Development of the VCaP androgen-independent model of prostate cancer. Urol Oncol 2006; 24 (2): 161-168. (Pubitemid 43340173)
28. Edwards J, Krishna NS, Grigor KM, Bartlett JM,. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003; 89 (3): 552-556. (Pubitemid 37026442)
29. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP,. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9 (4): 401-406.
30. Jenster G, Trapman J, Brinkmann AO,. Nuclear import of the human androgen receptor. Biochem J 1993; 293 (Pt 3): 761-768. (Pubitemid 23244561)
31. Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP,. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 2002; 277 (29): 26321-26326. (Pubitemid 34967123)
32. Waller AS, Sharrard RM, Berthon P, Maitland NJ,. Androgen receptor localisation and turnover in human prostate epithelium treated with the antiandrogen, Casodex. J Mol Endocrinol 2000; 24 (3): 339-351. (Pubitemid 30415008)
33. Gelmann EP,. Molecular biology of the androgen receptor. J Clin Oncol 2002; 20 (13): 3001-3015. (Pubitemid 34728896)
34. Heinlein CA, Chang C,. Androgen receptor in prostate cancer. Endocr Rev 2004; 25 (2): 276-308. (Pubitemid 38501396)
35. Prescott J, Coetzee GA,. Molecular chaperones throughout the life cycle of the androgen receptor. Cancer Lett 2006; 231 (1): 12-19. (Pubitemid 41779448)
36. Cutress ML, Whitaker HC, Mills IG, Stewart M, Neal DE,. Structural basis for the nuclear import of the human androgen receptor. J Cell Sci 2008; 121 (Pt 7): 957-968. (Pubitemid 351639415)
37. Haelens A, Tanner T, Denayer S, Callewaert L, Claessens F,. The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor. Cancer Res 2007; 67 (9): 4514-4523. (Pubitemid 46815103)
38. Kawate H, Wu Y, Ohnaka K, Tao RH, Nakamura K, Okabe T, Yanase T, Nawata H, Takayanagi R,. Impaired nuclear translocation, nuclear matrix targeting, and intranuclear mobility of mutant androgen receptors carrying amino acid substitutions in the deoxyribonucleic acid-binding domain derived from androgen insensitivity syndrome patients. J Clin Endocrinol Metab 2005; 90 (11): 6162-6169. (Pubitemid 41606539)
39. Cousty-Berlin D, Bergaud B, Bruyant MC, Battmann T, Branche C, Philibert D,. Preliminary pharmacokinetics and metabolism of novel non-steroidal antiandrogens in the rat: Relation of their systemic activity to the formation of a common metabolite. J Steroid Biochem Mol Biol 1994; 51 (1-2): 47-55. (Pubitemid 24340045)
40. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL,. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324 (5928): 787-790.
41. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL,. Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study. Lancet 2010; 375 (9724): 1437-1446.